SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Orchid Pharma - Quaterly Results

12 Feb 2022 Evaluate
The turnover for the December 2021 quarter moved up 55.21% to Rs. 1592.95 millions as compared to Rs. 1026.30 millions during the year-ago period.The Net Loss for the quarter ended December 2021 is Rs. -87.48 millions as compared to Net Loss of Rs. -453.31 millions of corresponding quarter ended December 2020 Operating profit Margin for the quarter ended December 2021 improved to 182.57% as compared to -38.05% of corresponding quarter ended December 2020


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202103 202003 % Var
Sales 1592.95 1026.30 55.21 3767.40 3302.01 14.09 4506.95 4812.09 -6.34
Other Income 23.66 17.37 36.21 72.56 39.40 84.16 64.75 242.77 -73.33
PBIDT 182.57 -38.05 -579.82 350.38 381.07 -8.05 643.62 336.08 91.51
Interest 67.81 125.33 -45.89 275.53 394.49 -30.16 513.36 41.59 1134.34
PBDT 114.76 -163.38 -170.24 74.85 -13.42 -657.75 130.26 294.49 -55.77
Depreciation 202.24 289.93 -30.25 603.94 885.77 -31.82 1088.99 1179.07 -7.64
PBT -87.48 -453.31 -80.70 -529.09 -899.19 -41.16 -958.73 -884.58 8.38
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -87.48 -453.31 -80.70 -529.09 -899.19 -41.16 -958.73 -884.58 8.38
Equity 408.16 408.16 0.00 408.16 408.16 0.00 408.16 408.16 0.00
PBIDTM(%) 11.46 -3.71 -409.13 9.30 11.54 -19.41 14.28 6.98 104.47

Orchid Pharma Share Price

570.50 6.40 (1.13%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×